Cardiovascular disease

Heart
#Cardiovascular disease #Molecular glue degrader #Monte Rosa Therapeutics #Phase I trial

Molecular glue degrader normalises key pathogenic drivers of ASCVD

In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader (MGD), was shown to normalise multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers.  Monte Rosa Therapeutics announced the finding along with other positive data from GFORCE-1, a Phase I study evaluating MRT-8102, which… Read More

#News

RNA strand
#Arrowhead Pharmaceuticals #Cardiovascular disease #Phase II trial #RNA therapy

Arrowhead’s RNA therapy silences two genes simultaneously

Arrowhead Pharmaceuticals has announced interim topline data from a Phase I/IIa clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia.   ARO-DIMER-PA is designed to silence expression of both… Read More

#News

Pulmonary hypertension
#Cardiovascular disease #Diabetes #Eli Lilly #FDA #GLP-1

FDA extends Mounjaro approval to include reducing cardiovascular risk

The US Food and Drug Administration (FDA) has approved Lilly’s Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE) in adults with type 2 diabetes.   The drug is already approved as an adjunct to diet and exercise to… Read More

#News #Regulatory

Heart
#Cardiovascular disease #ESC Congress #IsomAb #Review

Landmark safety data support therapeutic angiogenesis

Safety evidence announced at the ESC Congress 2026 by Isomab has reinforced the potential of a new class of therapies designed to promote blood vessel growth as a disease-modifying approach for coronary artery disease (CAD).   The systematic review of clinical trial data evaluating growth factor approaches, spanning… Read More

#News

Cardiovascular system
#Cardiovascular disease #Cytokinetics #MHRA #National Institute for Health and Care Excellence (NICE)

Myqorzo gets concurrent approvals from UK’s MHRA and NICE

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Myqorzo (aficamten) a marketing authorisation across the UK for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM).   At the same time, the National Institute for Health and Care Excellence (NICE) has issued guidance… Read More

#News #Regulatory

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Cholesterol test
#Cardiovascular disease #Cholesterol #Eli Lilly #Gene therapy

Single-shot gene therapy could cut cholesterol by 62% 

A single-shot gene therapy could slash cholesterol levels by 62%, potentially ‘transforming cardiovascular care’.  Results from the Heart-2 study into VERVE-102, published in The New England Journal of Medicine, showed reductions of up to 62% in a cohort of 35 participants, with durability observed for up… Read More

#News

Human heart
#Cardiovascular disease #Drug development #Heart disease #Preclinical development

Human-first heart development

Ronald A Li, CEO and Co-Founder at Medera, explores how human-centred preclinical models are transforming cardiovascular drug development. When we published our previous article in Drug Discovery World last September, we argued that human-based mini-Heart technology could fundamentally reshape cardiovascular drug development by reducing reliance on animal models and improving translational predictability. That argument, grounded in strong science, ultimately required patient validation.  Today, that validation is emerging at scale.  … Read More

#Exclusive Content

Heart
#Alnylam Pharmaceuticals #Cardiovascular disease #Collaboration #Tenaya Therapeutics

Alnylam and Tenaya agree cardiovascular disease collab

Alnylam Pharmaceuticals and Tenaya Therapeutics have agreed a research collaboration to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.  Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets.   In return, Tenaya will receive up to $10 million… Read More

#Business & Investment #News

siRNA
#Atrium Therapeutics #Cardiovascular disease #RNA #Start-ups

New launch Atrium will focus on RNA medicines for cardiomyopathy

Atrium Therapeutics has launched as a newly independent, publicly traded company developing RNA therapeutics for people living with rare, life-threatening genetic cardiomyopathies.   Atrium Therapeutics was established in connection with Avidity Biosciences’ acquisition by Novartis. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO), and begins operations… Read More

#Business & Investment #News #Start-up Zone

Lab professionals
#Acute inflammatory conditions #Cardiovascular disease #Molecular glue degrader #Monte Rosa Therapeutics #Phase I trial

Molecular glue degrader reduces systemic inflammation

Monte Rosa Therapeutics has shared positive interim data from an ongoing Phase I clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.  “These remarkable interim data from our ongoing Phase I study of… Read More

#News

CRISPR gene editing
#Cardiovascular disease #Cholesterol #CRISPR #CRISPR Therapeutics #CRISPR-Cas9 #Phase I trial

In vivo CRISPR gene editing therapy lowers cholesterol

CRISPR Therapeutics has shared positive Phase I data from an ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3.   A single-course treatment with CTX310 produced dose-dependent, durable reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum… Read More

#News #Trending News

CRISPR gene editing
#Cardiovascular disease #Gene editing #Gene therapy #Intellia Therapeutics #Phase III trial

Intellia pauses gene therapy trial due to liver injury

Intellia Therapeutics announced it has temporarily paused its MAGNITUDE and MAGNITUDE-2 Phase III clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively.  The action follows a report of Grade 4 liver transaminases and increased total bilirubin in a patient who… Read More

#Editor's Choice #News

Ozempic (semaglutide)
#Cardiovascular disease #GLP-1 #Novo Nordisk #University College London

Semaglutide protects heart beyond weight loss benefits

Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, says a new study led by University College London (UCL).  The finding, the researchers say, suggests there are multiple ways the drug… Read More

#News #Trending News

Human heart
#Cardiovascular disease #Clinical trials #Drug development #Drug discovery

Can human mini-Hearts advance cardiovascular drug development?

By Ronald A Li, PhD, CEO and Co-Founder, Medera, and Kevin D Costa, PhD, Co-Founder, Novoheart. Recent NIH policy prioritising the use of New Approach Methodologies (NAMs) as alternatives to laboratory animals in all new funding opportunities marks a seismic shift in how biomedical research will be conducted. For a… Read More

#Exclusive Content